GlassScriptPhysician profile
Rebecca E Hagensee
NPI 1992089890
$3,177.92
in general payments reported to CMS, 2019-2025
16 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 88% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
See the full distribution for Adult Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $351 · 2022: $270 · 2023: $436 · 2024: $750 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,556.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $818.18 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $286.63 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $284.01 | 2023-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $270.22 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $212.83 | 2024-2025 | Wegovy, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $204.43 | 2021-2024 | Lifevest |
| Cvrx, INC. | $200.05 | 2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $187.04 | 2023-2025 | |
| Scpharmaceuticals INC. | $182.12 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.42 | 2021-2022 | |
| Pfizer INC. | $85.07 | 2025 | |
| Boston Scientific Corporation | $84.35 | 2023-2024 | Watchman Access System, Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $81.37 | 2024-2025 | Wainua, Lokelma, Farxiga |
| Regeneron Healthcare Solutions, INC. | $51.84 | 2025 | Evkeeza, Praluent |
| Bridgebio Pharma, INC. | $37.54 | 2025 | Attruby |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $18.82 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Hagensee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.